Therma Bright (THRM) AI Stock Analysis

• Market Cap: C$9.09M
• Dividend Yield: N/A
• Average Volume (3M): 579.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 69.93%
• EPS Growth: 20.54%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 454,457,150
• 10 Day Avg. Volume: 460,540
• 30 Day Avg. Volume: 579,163
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 644.30
• Price to Cash Flow (P/CF): -19.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Therma Bright's overall stock score reflects a company facing significant financial and operational challenges, with weak technical indicators and a negative valuation profile. However, recent strategic corporate events provide a potential for improved market positioning and growth prospects. The significant financial challenges and weak technical signals are primary concerns, balanced partly by promising corporate developments.

Therma Bright Business Overview & Revenue Model

Company Description

Therma Bright Inc. (THRM) is a medical device company focused on developing innovative diagnostic and therapeutic solutions. The company operates within the biotechnology and healthcare sectors, offering products designed to provide effective, non-invasive treatments for various medical conditions. Its core offerings include a range of medical devices and technologies aimed at improving patient care and outcomes.

How the Company Makes Money

Therma Bright generates revenue primarily through the sale and distribution of its medical devices and technologies. The company's revenue streams include direct sales to healthcare providers and distributors, licensing agreements, and potential partnerships with other medical companies. Additionally, Therma Bright may engage in research and development collaborations that could provide financial returns through joint ventures or co-development agreements. These partnerships and agreements are significant contributors to its earnings, allowing the company to leverage external expertise and resources to expand its market reach.

Therma Bright Financial Statement Overview

Summary

Therma Bright's financials reflect significant challenges with ongoing profitability and liquidity issues. Despite revenue growth and a stable balance sheet, the company faces persistent losses and negative cash flows, indicating substantial operational and financial risks.

Income Statement

Therma Bright has experienced fluctuating revenue growth, with a notable increase in TTM (Trailing-Twelve-Months). However, the company remains unprofitable with negative net profit margins, EBIT, and EBITDA margins consistently over the years, indicating ongoing operational challenges.

Balance Sheet

The company's balance sheet shows moderate leverage with a low debt-to-equity ratio. However, the return on equity is negative due to persistent losses. The equity ratio has improved, indicating better asset financing through equity rather than debt.

Cash Flow

Therma Bright's cash flow statement shows negative free cash flow and operating cash flow, highlighting liquidity issues. While there is some improvement in operating cash flow to net income ratio, the free cash flow to net income ratio remains weak.

Breakdown
Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
26.07K	23.90K	139.43K	3.88K	3.78K
	Gross Profit
25.46K	23.90K	63.48K	3.88K	3.78K
	EBIT
-1.14M	-3.60M	-5.68M	-8.54M	-607.13K
	EBITDA
-2.34M	-3.68M	-5.83M	-8.55M	-606.31K
	Net Income Common Stockholders
-2.45M	-3.77M	-5.88M	-8.61M	-626.68K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.10K	182.24K	3.08M	1.78M	1.06M
	Total Assets
3.19M	2.21M	4.00M	2.24M	1.15M
	Total Debt
65.39K	90.39K	110.55K	40.00K	95.94K
	Net Debt
64.30K	-91.85K	-2.97M	-1.74M	-965.83K
	Total Liabilities
1.87M	2.16M	1.25M	927.12K	924.32K
	Stockholders Equity
1.32M	44.79K	2.75M	1.32M	223.97K
Cash Flow		Free Cash Flow
-1.01M	-2.44M	-3.80M	-3.16M	-104.94K
	Operating Cash Flow
-1.01M	-2.17M	-3.80M	-2.86M	-104.94K
	Investing Cash Flow
-138.26K	-691.08K	-204.93K	-300.00K	0.00
	Financing Cash Flow
966.40K	-33.60K	5.31M	3.87M	1.14M

Therma Bright Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:THRM, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.23 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:THRM.

Therma Bright Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GUD	65 Neutral	C$586.75M	134.09	0.53%	―	13.13%	―
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
THRM	45 Neutral	C$9.09M	―	-203.19%	―	69.93%	20.54%
BCT	41 Neutral	C$26.93M	―	-478.64%	―	―	56.78%
SVA	33 Underperform	C$62.41M	―	248.46%	―	―	32.71%

Therma Bright Corporate Events

Therma Bright Gains Market Traction with New Venowave Order

Therma Bright Inc. has secured an initial purchase order for 200 units of its Venowave VW5 product from a key distributor in the Durable Medical Equipment sector, indicating strong market confidence in its offerings. This development highlights the potential for significant follow-on orders and expansion opportunities, as the company continues to navigate the global trade environment and manage debt settlements through share issuance.

Spark’s Take on TSE:THRM Stock

According to Spark, TipRanks’ AI Analyst, TSE:THRM is a Neutral.

Therma Bright’s overall stock score reflects a company facing financial and operational challenges, with weak technical indicators and a negative valuation profile. However, recent strategic corporate events provide a potential for improved market positioning and growth prospects.

To see Spark’s full report on TSE:THRM stock, click here.

Therma Bright Reviews Manufacturing Strategy Amid US Tariff Changes

Therma Bright Inc. is reviewing its manufacturing strategy for the Venowave device due to recent US tariff changes on goods from China, which could increase costs for products sold in the US. The company is considering onshoring manufacturing to North America or a hybrid approach to mitigate tariff impacts, while also evaluating factors such as supply chain resilience, lead times, and quality control. No final decision has been made yet, but Therma Bright is committed to keeping stakeholders informed as they navigate this evolving situation. Additionally, the company is working with national distributors to expand the market presence of Venowave, a compact, battery-operated device designed to enhance vascular and lymphatic flow in the lower limbs.

Spark’s Take on TSE:THRM Stock

According to Spark, TipRanks’ AI Analyst, TSE:THRM is a Neutral.

Therma Bright’s overall stock performance is hindered by significant financial challenges, including declining revenues and negative profitability. While the technical indicators suggest a bearish trend, recent positive corporate events offer potential for market expansion and improved financial stability. However, the negative valuation metrics reflect ongoing profitability concerns, contributing to a lower overall score.

To see Spark’s full report on TSE:THRM stock, click here.

Therma Bright Secures Exclusive U.S. Distribution Deal with Global Wellness

Therma Bright Inc. has secured an exclusive U.S. marketing and distribution contract with Global Wellness Products LLC for its consumer products, starting with the InterceptCS cold sore prevention device. This partnership aims to tap into the growing global cold sore treatment market, which was valued at USD 1.02 billion in 2024 and is projected to reach USD 1.57 billion by 2031, expanding Therma Bright’s market presence and product reach.

Therma Bright Strengthens Advisory Board and Settles Debt to Enhance Growth

Therma Bright has appointed healthcare and technology expert Steve Raysely to its Advisory Board, enhancing its strategic capabilities in market positioning and technology deployment. Additionally, the company has settled significant debt through the issuance of common shares, which is expected to support its financial stability and growth efforts.